TWI809967B - (s, e)-4-(二甲胺基)-n-(3-(4-(2-羥基-1-苯乙胺基)-6-苯基呋喃并[2,3-d]嘧啶-5-基)苯基)丁-2-烯醯胺游離鹼之晶型 - Google Patents

(s, e)-4-(二甲胺基)-n-(3-(4-(2-羥基-1-苯乙胺基)-6-苯基呋喃并[2,3-d]嘧啶-5-基)苯基)丁-2-烯醯胺游離鹼之晶型 Download PDF

Info

Publication number
TWI809967B
TWI809967B TW111125153A TW111125153A TWI809967B TW I809967 B TWI809967 B TW I809967B TW 111125153 A TW111125153 A TW 111125153A TW 111125153 A TW111125153 A TW 111125153A TW I809967 B TWI809967 B TW I809967B
Authority
TW
Taiwan
Prior art keywords
cancer
crystal form
pharmaceutical composition
abt
free base
Prior art date
Application number
TW111125153A
Other languages
English (en)
Chinese (zh)
Other versions
TW202309041A (zh
Inventor
徐祖安
謝興邦
張書銘
Original Assignee
石 全
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 石 全 filed Critical 石 全
Publication of TW202309041A publication Critical patent/TW202309041A/zh
Application granted granted Critical
Publication of TWI809967B publication Critical patent/TWI809967B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW111125153A 2021-07-06 2022-07-05 (s, e)-4-(二甲胺基)-n-(3-(4-(2-羥基-1-苯乙胺基)-6-苯基呋喃并[2,3-d]嘧啶-5-基)苯基)丁-2-烯醯胺游離鹼之晶型 TWI809967B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163218504P 2021-07-06 2021-07-06
US63/218,504 2021-07-06

Publications (2)

Publication Number Publication Date
TW202309041A TW202309041A (zh) 2023-03-01
TWI809967B true TWI809967B (zh) 2023-07-21

Family

ID=84802010

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111125153A TWI809967B (zh) 2021-07-06 2022-07-05 (s, e)-4-(二甲胺基)-n-(3-(4-(2-羥基-1-苯乙胺基)-6-苯基呋喃并[2,3-d]嘧啶-5-基)苯基)丁-2-烯醯胺游離鹼之晶型

Country Status (12)

Country Link
US (2) US12240858B2 (enExample)
EP (1) EP4330259A4 (enExample)
JP (1) JP7565118B2 (enExample)
KR (1) KR102783648B1 (enExample)
CN (1) CN116916922B (enExample)
AU (1) AU2022307875B2 (enExample)
BR (1) BR112023024853A2 (enExample)
CA (1) CA3217088A1 (enExample)
IL (1) IL308946B2 (enExample)
MX (1) MX2023013093A (enExample)
TW (1) TWI809967B (enExample)
WO (1) WO2023283269A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI906763B (zh) * 2024-02-05 2025-12-01 財團法人國家衛生研究院 表皮生長因子受體抑制劑

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201018696A (en) * 2008-11-10 2010-05-16 Nat Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101301533B1 (ko) * 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201018696A (en) * 2008-11-10 2010-05-16 Nat Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors

Also Published As

Publication number Publication date
TW202309041A (zh) 2023-03-01
JP2024514995A (ja) 2024-04-04
US12240858B2 (en) 2025-03-04
IL308946A (en) 2024-01-01
KR102783648B1 (ko) 2025-03-18
IL308946B2 (en) 2026-01-01
CA3217088A1 (en) 2023-01-12
BR112023024853A2 (pt) 2024-02-15
CN116916922A (zh) 2023-10-20
WO2023283269A1 (en) 2023-01-12
AU2022307875A1 (en) 2023-11-02
CN116916922B (zh) 2026-01-02
AU2022307875B2 (en) 2024-08-01
US20230021909A1 (en) 2023-01-26
EP4330259A4 (en) 2024-10-09
KR20230118963A (ko) 2023-08-14
EP4330259A1 (en) 2024-03-06
JP7565118B2 (ja) 2024-10-10
IL308946B1 (en) 2025-09-01
US20240368175A1 (en) 2024-11-07
MX2023013093A (es) 2024-04-09

Similar Documents

Publication Publication Date Title
TW202311259A (zh) 化合物i的新形式及其應用
JP4456079B2 (ja) ｛６，７−ビス（２−メトキシ−エトキシ）−キナゾリン−４−イル｝−（３ｅ）の多形体
CN108349978A (zh) (S)-4-(8-氨基-3-(1-(丁-2-炔酰基)吡咯烷-2-基)咪唑并[1,5-a]吡嗪-1-基)-N-(吡啶-2-基)苯甲酰胺的固体形式和制剂
TWI809967B (zh) (s, e)-4-(二甲胺基)-n-(3-(4-(2-羥基-1-苯乙胺基)-6-苯基呋喃并[2,3-d]嘧啶-5-基)苯基)丁-2-烯醯胺游離鹼之晶型
CN107793363B (zh) 一种取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用
TWI638818B (zh) ２－（４－（２－（１－異丙基－３－甲基－１ｈ－１，２，４－三唑－５－基）－５，６－二氫苯并［ｆ］咪唑并［１，２－ｄ］［１，４］氧氮呯－９－基）－１ｈ－吡唑－１－基）－２－甲基丙醯胺之多晶型、製造方法及醫藥用途
RU2851691C2 (ru) Кристаллические формы свободного основания (S,E)-4-(диметиламино)-N-(3-(4-(2-гидрокси-1-фенилэтиламино)-6-фенилфуро[2,3-d]пиримидин-5-ил)фенил)бут-2-енамида
HK40094095A (zh) (s，e)-4-(二甲胺基)-n-(3-(4-(2-羟基-1-苯乙胺基)-6-苯基呋喃并[2，3-d]嘧啶-5-基)苯基)丁-2-烯醯胺游离硷的晶型
TW201811326A (zh) ４－氰基－ｎ－（２－（４，４－二甲基環己－１－烯－１－基）－６－（２，２，６，６－四甲基四氫－２ｈ－哌喃－４－基）吡啶－３－基）－１ｈ－咪唑－２－甲醯胺之鹽形式
TWI752980B (zh) 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之晶型
AU2014280711B2 (en) Polymorphic forms of Icotinib and uses thereof
TW202517624A (zh) Mek免疫腫瘤抑制劑醫藥組合物
TW201829398A (zh) 酪胺酸蛋白激酶調節劑、晶型及其用途
TW202413343A (zh) ５－（２－（４－（４－氟－２－甲基－１ｈ－吲哚－５－基氧基）－６－甲氧基喹啉－７－基氧基）乙基）－５－氮雜螺［２．４］－庚－７－醇之結晶、磷酸鹽及其對映體之生物活性
CN120344512A (zh) 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
TWI596098B (zh) 埃克替尼馬來酸鹽的晶型及其用途
HK40126640A (zh) 喹唑啉erbb抑制剂的药物形式
CN120037236A (zh) 晶体、药物组合物及其制备方法和应用